Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy

被引:41
|
作者
Zanchetta, Marisa
Walker, Sarah
Burighel, Nicoletta
Bellanova, Domenico
Rampon, Osvalda
Giaquinto, Carlo
De Rossi, Anita
机构
[1] Univ Padua, Dept Oncol & Surg Sci, Unite Oncol Virale, AIDS Reference Ctr, Padua, Italy
[2] Med Res Ctr, Clin Trials Unit, London, England
[3] Univ Padua, Dept Pediat, Padua, Italy
来源
JOURNAL OF INFECTIOUS DISEASES | 2006年 / 193卷 / 12期
基金
英国医学研究理事会;
关键词
D O I
10.1086/504264
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To investigate the decay of the human immunodeficiency virus type 1 (HIV-1) reservoir in children receiving highly active antiretroviral therapy (HAART), we measured HIV-1 DNA in peripheral blood mononuclear cells from 14 children who achieved and maintained suppression of plasma viremia up to 48 months after the initiation of HAART. Levels of intracellular unspliced and multiply spliced HIV-1 RNA were used as markers of residual viral replication. During the first month of HAART, there were significant decays in levels of both plasma HIV-1 RNA and multiply spliced HIV-1 RNA, yet unspliced HIV-1 RNA persisted in most of the children. Greater HIV-1 DNA decay during the first month of HAART correlated with a higher concomitant increase in CD4(+) cell counts (P = .028) and a smaller subsequent HIV-1 DNA decay (P = .0012). Furthermore, HIV-1 DNA decayed faster from 1 to 9 months of HAART (median half-life, 5 months) than during the subsequent follow-up period (median half-life, 30 months). Moreover, after 9 months of HAART, HIV-1 DNA tended to decay more slowly in children with detectable levels of unspliced HIV-1 RNA. These findings suggest that clearance of the viral reservoir in HAART-treated children may be influenced by immune repopulation and residual viral replication and may help in refining long-term treatment strategies.
引用
收藏
页码:1718 / 1727
页数:10
相关论文
共 50 条
  • [31] Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy
    Kaufmann, GR
    Bloch, M
    Zaunders, JJ
    Smith, D
    Cooper, DA
    AIDS, 2000, 14 (08) : 959 - 969
  • [32] Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients
    Imahashi, Mayumi
    Ode, Hirotaka
    Kobayashi, Ayumi
    Nemoto, Michiko
    Matsuda, Masakazu
    Hashiba, Chieko
    Hamano, Akiko
    Nakata, Yoshihiro
    Mori, Mikiko
    Seko, Kento
    Nakahata, Masashi
    Kogure, Ayumi
    Tanaka, Yasuhito
    Sugiura, Wataru
    Yokomaku, Yoshiyuki
    Iwatani, Yasumasa
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [33] Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients
    Mayumi Imahashi
    Hirotaka Ode
    Ayumi Kobayashi
    Michiko Nemoto
    Masakazu Matsuda
    Chieko Hashiba
    Akiko Hamano
    Yoshihiro Nakata
    Mikiko Mori
    Kento Seko
    Masashi Nakahata
    Ayumi Kogure
    Yasuhito Tanaka
    Wataru Sugiura
    Yoshiyuki Yokomaku
    Yasumasa Iwatani
    Scientific Reports, 11
  • [34] Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy
    Frater, AJ
    Dunn, DT
    Beardall, AJ
    Ariyoshi, K
    Clarke, JR
    McClure, MO
    Weber, JN
    AIDS, 2002, 16 (08) : 1139 - 1146
  • [35] Bacterial Meningitis in HIV-1-infected Patients in the Era of Highly Active Antiretroviral Therapy
    Domingo, Pere
    Suarez-Lozano, Ignacio
    Torres, Ferran
    Pomar, Virginia
    Ribera, Esteban
    Jose Galindo, Ma
    Cosin, Jaime
    Luisa Garcia-Alcalde, Ma
    Vidal, Francesc
    Lopez-Aldeguer, Jose
    Roca, Bernardino
    Gonzalez, Juan
    Lozano, Fernando
    Garrido, Myriam
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 (05) : 582 - 587
  • [36] Effectiveness of highly active antiretroviral therapy among HIV-1 infected women
    Gange, SJ
    Barrón, Y
    Greenblatt, RM
    Anastos, K
    Minkoff, H
    Young, M
    Kovacs, A
    Cohen, M
    Meyer, WA
    JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2002, 56 (02) : 153 - 159
  • [37] Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
    Schneider, MME
    Borleffs, JCC
    Stolk, RP
    Jaspers, CAJJ
    Hoepelman, AIM
    LANCET, 1999, 353 (9148): : 201 - 203
  • [38] Persistent subclinical immune defects in HIV-1-infected children treated with antiretroviral therapy
    van den Heuvel, Diana
    Driessen, Gertjan J. A.
    Berkowska, Magdalena A.
    van der Burg, Mirjam
    Langerak, Anton W.
    Zhao, Dan
    Charif, Halima
    Hartwig, Nico G.
    van Rossum, Annemarie M. C.
    Fraaij, Pieter L. A.
    van Dongen, Jacques J. M.
    van Zelm, Menno C.
    AIDS, 2015, 29 (14) : 1745 - 1756
  • [39] Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy
    Clerici, M
    Saresella, M
    Trabattoni, D
    Ferrante, P
    Vanzulli, A
    Vigano, A
    AIDS, 2002, 16 (16) : 2219 - 2221
  • [40] Immune reconstitution in HIV-1 infected patients treated for two years with highly active antiretroviral therapy
    Almeida, R. A. M. B.
    Souza, L. R.
    Calvi, S. A.
    Ikoma, M. R., V
    Silva, V. A.
    Curi, P. R.
    Meira, D. A.
    JOURNAL OF VENOMOUS ANIMALS AND TOXINS INCLUDING TROPICAL DISEASES, 2006, 12 (01) : 91 - 109